Nomograms for predicting short-term mortality in acute-on-chronic liver disease caused by the combination of hepatitis B virus and alcohol

Hongqin Xu(Jilin University), Yanhang Gao(Jilin University), Huadong Yan(Zhejiang Shuren University), Guohong Deng(University of Groningen), Xinyi Zhou(Shanghai Medical College of Fudan University), Qun Zhang(Union Hospital), Zhongji Meng(Hubei University of Medicine), Shuning Sun(Beijing Tongren Hospital), Weituo Zhang(Tongren Hospital), Ruochan Chen(Central South University), Wenting Tan(Army Medical University), Yu Shi(Tongji University), Yixin Hou(Wuhan National Laboratory for Optoelectronics), Yi Zhou(Army Medical University), Guotao Zhong(Nanfang Hospital), Xin Zheng(Wuhan Union Hospital), Beiling Li(Key Laboratory of Guangdong Province), Sen Luo(Hubei University of Medicine), Jing Liu(Sichuan University), Haiyu Wang(Jilin University), Feng Liu(Peking University), Hai Li(Shanghai Jiao Tong University), Yuanyuan Chen(Jahra Hospital), Tao Li(Yangtze University), Yan Zhang(Sichuan Provincial Hospital of Traditional Chinese Medicine), Yan Xiong, Wen Gu(University Hospital Münster), Xiaobo Lu(Xinjiang Medical University), Xiaoyu Wen(Jilin University), Jing Li(Capital Medical University), Xianbo Wang(Capital Medical University), Jinjun Chen(Southern Medical University), Min Zhang(Central South University), Feng Yue(Capital Medical University), Zhiping Qian(Shanghai Public Health Clinical Center), Yan Huang(Central South University), Liang Qiao(The University of Sydney), Rongjiong Zheng(Xinjiang Medical University), Haotang Ren(National Clinical Research Center for Digestive Diseases), Xiuhua Jiang(Key Laboratory of Guangdong Province), Tao Liu(Zhongda Hospital Southeast University), Yubao Zheng(Sun Yat-sen University)
Scientific Reports
October 19, 2024
10.1038/s41598-024-76473-z
Cited by 1

Related Papers

The mechanism of HMGB1 secretion and release
|Experimental & Molecular Medicine|2022|793
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth
|Nature Communications|2017|350
Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey
|BMJ|2023|286